Propanc Biopharma Inc

PPCB Healthcare Biotechnology

In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.

0.34 0.00 0.00%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Jun '23 Jun '24 Jun '25 Jun '26
Current Ratio
0.01 0.01 0.02 0.02 0.00 0.00 0.01 0.01 1.50 2.55
Net Debt/EBITDA
0.00 (0.01) (0.02) 0.00 (0.03) (0.02) (0.06) (0.20) (0.01) 0.02
Debt/Assets
62.15% 76.75% 51.03% 51.78% 423.66% 62.67% 190.05% 448.62% 2.99% 3.61%
Debt/Equity
(0.01) (0.01) (0.01) (0.01) (0.02) (0.02) (0.04) (0.09) 0.04 0.05
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
0.26 0.31 0.36 0.39 0.47 0.43 0.35 0.46 0.01 0.29
Capex/Depreciation
0.00 0.00 (1.26) 0.00 0.00 0.00 0.00 0.00 — (4.90)
Interest Coverage
(1.79) (1.42) (1.99) (2.00) (4.03) (3.50) (3.33) (2.31) (101.59) (42.24)
ROE
196.27% 115.36% 104.10% 119.22% 71.97% 110.09% 101.75% 58.39% (1,163.68%) (169.86%)
ROA
(3,318.22%) (8,455.50%) (6,653.26%) (4,735.96%) (4,332.80%) (7,085.23%) (4,403.94%) (3,034.66%) (598.08%) (122.15%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (247.22%) (125.86%)
Return on Tangible Assets
144.52% 104.22% 133.81% 129.34% 78.76% 110.26% 99.61% 53.09% (2,123.67%) (381.25%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% — 0.00% 0.00% 0.00% 0.00% — — 0.00%
Free Cash Flow per Share
(0.58) (55.27) (3.93) (75.19) (0.38) (21.06) (0.64) (9,351.00) (2.55) (5.06)
Cash per Share
0.02 0.51 0.00 2.72 0.00 0.06 0.01 211.00 0.08 0.74
Shareholders Equity per Share
(1.55) (171.37) (8.19) (148.02) (1.01) (44.33) (1.79) (37,791.00) 87.63 8.37
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(1.55) (171.37) (8.19) (148.02) (1.01) (44.33) (1.79) (37,791.00) 87.63 8.37
Free Cash Flow
(2.05) (2.18) (2.06) (1.85) (1.15) (1.44) (1.11) (0.94) (0.41) (5.69)
Working Capital
(5.45) (6.76) (4.31) (3.67) (3.07) (3.05) (3.14) (3.77) 2.77 5.19
Capital Expenditures
— — 0.00 — — — — — — 0.00
Net Current Asset Value
(5.45) (6.76) (4.31) (3.67) (3.07) (3.09) (3.16) (3.83) 2.63 5.16
Other line items
Quick Ratio
0.01 0.00 0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.25
Depreciation/Fixed assets
0.20 0.27 0.27 0.44 0.47 1.00 5.67 (0.01) — 0.26
Cash ROIC
38.59% 32.61% 48.57% 52.49% 38.05% 48.39% 36.93% 27.24% (2.79%) (53.18%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(0.58) (55.27) (3.92) (75.19) (0.38) (21.06) (0.64) (9,351.00) (2.55) (5.06)
Capex per Share
0.00 0.00 (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Average Payables
0.43 0.82 1.04 0.88 0.92 0.97 0.95 1.09 1.23 1.19
Average Assets
0.24 0.08 0.09 0.10 0.06 0.05 0.07 0.07 9.85 16.21
Average Common Equity
(4.01) (6.10) (5.53) (3.98) (3.36) (3.05) (3.07) (3.45) 5.06 11.65
Capex to Sales
— — 0.00 — — — — — — 0.00

Fold the line items

Columns are period end dates · fundamentals updated 6 Oct 2026